RxDoctor Payments Data

Jeanne-Elyse Cedeno, MD

Family Medicine · Los Lunas, NMNPI 1184867202

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Braeburn Inc. at 32.3% of the total.

$423in general payments, 2019–2025

Across 13 payments — averaging $32.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Braeburn Inc.$137
  • Gilead$85
  • Masimo Corporation$51
  • Boehringer Ingelheim$31
  • Lilly USA, LLC$28
  • Novo Nordisk$24
  • plus $68 from 4 others
$60,431in research payments, 2019–2025

Across 70 payments — averaging $863.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim Canada Ltd.ltee$42K
  • Boehringer Ingelheim$7K
  • Gilead$7K
  • Esperion Therapeutics, Inc.$4K

What the payments were for

  • Food & beverage$423100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$423 in reported general payments places this provider in the 70th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$10,323
Medicare patients
95
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide37$40,561
Gabapentin17$148
Duloxetine Hcl11$104
Finasteride14$63
Pantoprazole Sodium12$46
Meloxicam11$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$28$40,56137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Los Lunas

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →